You are here: Home > What is Heptromic? > Strategic impact
What is Heptromic?

Strategic impact

HEPTROMIC will optimise decision-making for liver cancer patients by identifying genomic prognostic determinants and oncogenic drivers.

Heptromic is a very bold and ambitious response to the core challenges in a new era of modern oncology.

We aim at improving health by identifying novel genomic predictors and oncogenic drivers of predictive tools and drivers of liver cancer that will, in the medium term, contribute to better allocation of resources and refinement of therapeutic strategies. In addition, with two small-medium enterprises in the team, the project will lead to the production of new, knowledge intensive products, creating sustainable employment and contributing to improving the world competitiveness of the European medical devices sector.

We will also help to throw new light on simple processes to link up all the stakeholders in the ‘triple helix’ of researchers and clinicians, business and regulators in the field of liver cancer which we expect will be transferrable to other medical fields.

Project led by: Idibaps

Copyright © 2010 - 2019 HEPTROMIC

HEPTROMIC is a project in the 'Health' Theme of the Specific Programme 'Cooperation' of the European Commission's Seventh Framework Programme.